Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Sequencing and curation strategies for identifying candidate glioblastoma treatments.

Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Geiger H, Felice V, Dikoglu E, Rahman S, Fang A, Vacic V, Bergmann EA, Vogel JLM, Reeves C, Khaira D, Calabro A, Kim D, Lamendola-Essel MF, Esteves C, Agius P, Stolte C, Boockvar J, Demopoulos A, Placantonakis DG, Golfinos JG, Brennan C, Bruce J, Lassman AB, Canoll P, Grommes C, Daras M, Diamond E, Omuro A, Pentsova E, Orange DE, Harvey SJ, Posner JB, Michelini VV, Jobanputra V, Zody MC, Kelly J, Parida L, Wrzeszczynski KO, Royyuru AK, Darnell RB.

BMC Med Genomics. 2019 Apr 25;12(1):56. doi: 10.1186/s12920-019-0500-0.

2.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK.

Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

PMID:
30675060
3.

Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.

Malani R, Bhatia A, Wolfe J, Grommes C.

Leuk Lymphoma. 2019 Jan 10:1-5. doi: 10.1080/10428194.2018.1563294. [Epub ahead of print]

PMID:
30628502
4.

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK.

Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19.

5.

Introduction of novel agents in the treatment of primary CNS lymphoma.

Grommes C, Nayak L, Tun HW, Batchelor TT.

Neuro Oncol. 2019 Feb 19;21(3):306-313. doi: 10.1093/neuonc/noy193.

PMID:
30423172
6.

Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT.

Neuro Oncol. 2019 Feb 19;21(3):296-305. doi: 10.1093/neuonc/noy192.

PMID:
30418592
7.

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE.

Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.

8.

Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.

Mendez JS, Grommes C.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:604-615. doi: 10.1200/EDBK_200829. Review.

PMID:
30231317
9.

Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.

Hatzoglou V, Oh JH, Buck O, Lin X, Lee M, Shukla-Dave A, Young RJ, Peck KK, Vachha B, Holodny AI, Grommes C.

J Neurooncol. 2018 Nov;140(2):351-358. doi: 10.1007/s11060-018-2960-z. Epub 2018 Aug 2.

PMID:
30073640
10.

Updates on Primary Central Nervous System Lymphoma.

Schaff LR, Grommes C.

Curr Oncol Rep. 2018 Feb 28;20(2):11. doi: 10.1007/s11912-018-0666-1. Review.

PMID:
29492682
11.

Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma.

Schram AM, Jonsson P, Drilon A, Bale TA, Hechtman JF, Benayed R, Hanusch B, Young RJ, Grommes C, Ku N, Kaley T, Hyman DM, Taylor BS.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00089. Epub 2018 Aug 8. No abstract available.

PMID:
31218270
12.

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.

Reiss SN, Yerram P, Modelevsky L, Grommes C.

J Immunother Cancer. 2017 Dec 19;5(1):99. doi: 10.1186/s40425-017-0302-x.

13.

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.

Oldrini B, Hsieh WY, Erdjument-Bromage H, Codega P, Carro MS, Curiel-García A, Campos C, Pourmaleki M, Grommes C, Vivanco I, Rohle D, Bielski CM, Taylor BS, Hollmann TJ, Rosenblum M, Tempst P, Blenis J, Squatrito M, Mellinghoff IK.

Nat Commun. 2017 Dec 11;8(1):2035. doi: 10.1038/s41467-017-02185-w.

14.

The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C.

Neuro Oncol. 2018 Apr 9;20(5):687-694. doi: 10.1093/neuonc/nox187.

15.

Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma.

Wrzeszczynski KO, Frank MO, Koyama T, Rhrissorrakrai K, Robine N, Utro F, Emde AK, Chen BJ, Arora K, Shah M, Vacic V, Norel R, Bilal E, Bergmann EA, Moore Vogel JL, Bruce JN, Lassman AB, Canoll P, Grommes C, Harvey S, Parida L, Michelini VV, Zody MC, Jobanputra V, Royyuru AK, Darnell RB.

Neurol Genet. 2017 Jul 11;3(4):e164. doi: 10.1212/NXG.0000000000000164. eCollection 2017 Aug.

16.

Primary CNS Lymphoma.

Grommes C, DeAngelis LM.

J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22. Review.

17.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

18.

Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

Grommes C, Younes A.

Cancer Cell. 2017 Jun 12;31(6):731-733. doi: 10.1016/j.ccell.2017.05.004. Epub 2017 May 25.

19.

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.

Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF.

J Clin Oncol. 2016 Jul 10;34(20):2404-15. doi: 10.1200/JCO.2016.66.6487. Epub 2016 May 9. Erratum in: J Clin Oncol. 2017 Jun 10;35(17):1972.

20.

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.

Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, Peck KK, Gutin P, Iorgulescu JB, Kaley T, DeAngelis L, Pentsova E, Nolan C, Grommes C, Chan T, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy P, Supko JG, Tabar V, Omuro A.

Clin Cancer Res. 2016 Oct 1;22(19):4786-4796. Epub 2016 May 6.

21.

Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.

Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM.

Oncologist. 2015 Jul;20(7):806-11. doi: 10.1634/theoncologist.2014-0149. Epub 2015 Jun 1.

22.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS.

Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7.

23.

Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.

Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT.

Clin Cancer Res. 2014 Oct 1;20(19):5023-31. doi: 10.1158/1078-0432.CCR-14-0822. Epub 2014 Aug 8.

24.

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

Khasraw M, Ameratunga M, Grommes C.

Expert Opin Biol Ther. 2014 May;14(5):729-40. doi: 10.1517/14712598.2014.898060. Epub 2014 Mar 22. Review.

PMID:
24655021
25.
26.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK.

Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.

27.

The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model.

Grommes C, Karlo JC, Caprariello A, Blankenship D, Dechant A, Landreth GE.

Cancer Chemother Pharmacol. 2013 Apr;71(4):929-36. doi: 10.1007/s00280-013-2084-2. Epub 2013 Jan 29.

PMID:
23358645
28.

Nervous system metastases from malignant mesothelioma.

Martinez NM, Gavrilovic IT, Grommes C.

Clin Oncol (R Coll Radiol). 2013 Jan;25(1):74. doi: 10.1016/j.clon.2012.10.001. Epub 2012 Oct 25. No abstract available.

PMID:
23103357
29.

Bevacizumab for the treatment of high-grade glioma.

Khasraw M, Simeonovic M, Grommes C.

Expert Opin Biol Ther. 2012 Aug;12(8):1101-11. doi: 10.1517/14712598.2012.694422. Epub 2012 Jun 5. Review.

PMID:
22663137
30.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

31.

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB.

Neuro Oncol. 2011 Dec;13(12):1364-9. doi: 10.1093/neuonc/nor121. Epub 2011 Aug 24.

32.

Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy.

Grommes C, Bosl GJ, DeAngelis LM.

Cancer. 2011 May 1;117(9):1911-6. doi: 10.1002/cncr.25693. Epub 2010 Nov 29.

33.

The stepping test: a step back in history.

Grommes C, Conway D.

J Hist Neurosci. 2011 Jan;20(1):29-33. doi: 10.1080/09647041003662255.

PMID:
21253937
34.

Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.

Redelman-Sidi G, Grommes C, Papanicolaou G.

J Neurooncol. 2011 Apr;102(2):335-9. doi: 10.1007/s11060-010-0322-6. Epub 2010 Jul 30.

PMID:
20676728
35.

Inverse association of PPARγ agonists use and high grade glioma development.

Grommes C, Conway DS, Alshekhlee A, Barnholtz-Sloan JS.

J Neurooncol. 2010 Nov;100(2):233-9. doi: 10.1007/s11060-010-0185-x. Epub 2010 May 5.

PMID:
20443132
36.

Corpus callosum dysgenesis limits MRI changes to one hemisphere in status epilepticus.

Grommes C, Oghlakian R, Blackham KA, De Georgia MA.

Neurology. 2009 Mar 10;72(10):942. doi: 10.1212/01.wnl.0000344186.12740.9a. No abstract available.

PMID:
19273832
37.

Steroid-responsive encephalopathy associated with autoimmune thyroiditis presenting with diffusion MR imaging changes.

Grommes C, Griffin C, Downes KA, Lerner AJ.

AJNR Am J Neuroradiol. 2008 Sep;29(8):1550-1. doi: 10.3174/ajnr.A1113. Epub 2008 Aug 13.

38.

Lambert-Eaton syndrome with large-cell neuroendocrine carcinoma of the lung.

Grommes C, Preston DC, Al-Kadhimi Z, Alshekhlee A.

Muscle Nerve. 2008 Jun;37(6):786-9. doi: 10.1002/mus.21032.

PMID:
18506722
39.

Cardiac papillary fibroelastoma mimicking left atrial appendage thrombus.

Barcena J, George JC, Grommes C, Blitz A, Gilkeson R, Hoit BD.

J Am Soc Echocardiogr. 2008 Oct;21(10):1177.e1-2. doi: 10.1016/j.echo.2007.10.017. Epub 2008 Jan 14.

PMID:
18248952
40.

Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases.

Grommes C, Lee CY, Wilkinson BL, Jiang Q, Koenigsknecht-Talboo JL, Varnum B, Landreth GE.

J Neuroimmune Pharmacol. 2008 Jun;3(2):130-40. doi: 10.1007/s11481-007-9090-2. Epub 2007 Oct 10.

41.

Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.

Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, Schlegel U, Heneka MT.

Mol Pharmacol. 2006 Nov;70(5):1524-33. Epub 2006 Aug 3.

PMID:
16887936
42.

Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia.

Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, Landreth G.

J Biol Chem. 2006 Jul 28;281(30):20842-50. Epub 2006 May 25.

43.
44.

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.

Grommes C, Landreth GE, Heneka MT.

Lancet Oncol. 2004 Jul;5(7):419-29. Review.

PMID:
15231248
45.

Different mechanisms of secondary neuronal damage in thalamic nuclei after focal cerebral ischemia in rats.

Dihné M, Grommes C, Lutzenburg M, Witte OW, Block F.

Stroke. 2002 Dec;33(12):3006-11.

PMID:
12468804
46.

Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma.

Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J, Heneka MT.

J Neurochem. 2002 Jun;81(5):1052-60.

47.

Retinal ischemia induced by the intraluminal suture method in rats.

Block F, Grommes C, Kosinski C, Schmidt W, Schwarz M.

Neurosci Lett. 1997 Aug 22;232(1):45-8.

PMID:
9292888

Supplemental Content

Loading ...
Support Center